Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Morgan Stanley Reaffirms Their Buy Rating on Gilead Sciences (GILD)

Tipranks - Tipranks - Sat Apr 11, 7:38AM CDT

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, with a price target of $175.00.

Easter Sale - 70% Off TipRanks

Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Moderna. According to TipRanks, Flynn has an average return of 9.8% and a 56.21% success rate on recommended stocks.

In addition to Morgan Stanley, Gilead Sciences also received a Buy from Oppenheimer’s Matthew Biegler in a report issued on April 8. However, on April 7, Goldman Sachs maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).

See the top stocks recommended by analysts >>

Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.93 billion and a net profit of $2.18 billion. In comparison, last year the company earned a revenue of $7.57 billion and had a net profit of $1.78 billion

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).